Last reviewed · How we verify
NCT04438954
Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels
trial in Multiple Sclerosis in 30 participants. Completed in 18 June 2020.
5 June 2020
Quick facts
| Lead sponsor | Ankara Yildirim Beyazıt University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 5 May 2020 |
| Primary completion | 5 June 2020 |
| Estimated completion | 18 June 2020 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
- Covid-19 — all drugs for Covid-19 →
Sponsor
Ankara Yildirim Beyazıt University
Who can join
Adults 21 to 58, any sex, with Multiple Sclerosis or Covid-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hundreds of thousands of confirmed cases have been reported worldwide, just 3 months after the first patients were identified in Wuhan, China. Just like other members of the community, MS patients are uncomfortable with the emotional distress and health anxiety caused by the COVID-19 outbreak. Most MS patients receive immunosuppressive or immunomodulatory therapies. Patients taking immunosuppressive agents are theoretically at increased risk of being affected by viral pandemics, and a higher health concern is expected in this group of patients. Moreover, MS patients lose social support. Patients with increased duration of stay can no longer access physical and cognitive rehabilitation therapies. We also know that increased anxiety and sleep disorders can cause MS patients to have an attack. When literature is examined, it is known that MS patients' physical activity levels decrease, fatigue, sleep quality and anxiety levels increase, so their quality of life and participation in daily life activities decrease. MS patients lose social support during the COVID-19 outbreak. For all these reasons, we think that the fatigue, physical activity level, anxiety level and sleep disturbances affected before the COVID-19 outbreak will be further affected for these reasons.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04438954
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Sclerosis
Currently open trials in the same condition.
- NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
- NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
- NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting
Other Ankara Yildirim Beyazıt University trials
Trials by the same sponsor.
- NCT07530835 — Occlusal Changes After Modified Hall Technique in Molars Affected by Molar-Incisor Hypomineralization · NA · not yet recruiting
- NCT07496853 — Effect of Upper Extremity Support on Spatiotemporal Parameters of Gait in Individuals With Stroke · NA · recruiting
- NCT07441668 — Comfort Intervention in PICU Children · NA · not yet recruiting
- NCT07431151 — Effects of Intensive Virtual Reality-Based Balance and Gait Training on Activity Performance and Quality of Life in Suba · NA · recruiting
- NCT07247903 — The Impact of Patient Education Delivered Through Virtual Reality · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04438954 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ankara Yildirim Beyazıt University
- Last refreshed: 22 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04438954.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing